| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AMGEN INC | EVP, Research and Development | Common Stock | 27,378 | $10,521,912 | $384.32 | 09 Feb 2026 | Direct |
| AMGEN INC | EVP, Research and Development | Nqso (Right to Buy) | 22,944 | $6,204,975 | $270.44 | 06 May 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AMGN | AMGEN INC | 09 Feb 2026 | 2 | -$1,192,929 | 4 | EVP, Research and Development | 10 Feb 2026, 18:39 |
| AMGN | AMGEN INC | 06 May 2025 | 2 | +$6,204,975 | 4 | EVP, R&D, & Chief Sci. Officer | 08 May 2025, 20:49 |
| AMGN | AMGEN INC | 07 May 2024 | 2 | +$5,586,481 | 4 | EVP, R&D, & Chief Sci. Officer | 09 May 2024, 18:59 |
| AMGN | AMGEN INC | 09 Feb 2024 | 2 | $0 | 4 | EVP, R&D, & Chief Sci. Officer | 12 Feb 2024, 19:50 |
| AMGN | AMGEN INC | 18 Dec 2023 | 0 | $0 | 3 | EVP, R&D, & Chief Sci. Officer | 19 Dec 2023, 20:38 |